Member Info for potnak

Think this is more of a nod to the LTH to say the deal isn't imminent but is coming. We won't get anything in the next few weeks IMO. At best, negotiations won't have started until after the WH Ireland RNS. So.. how long does it take to thrash a deal out. Will we be notified of a closed period? All good here just got to keep being patient.

Parker and wife have enough shares to retire on. IF the sp is big enough. I don't hold enough to retire, not unless Thoth is thinking 40p+ is coming. I certainly wouldn't be working as hard on anything more than 20p

I'm trying not to get excited because we've been here before, many times! At the current stage of drug development. Worst case scenario is candidate selection news, a rise to 1p and the usual retrace. That's what I'm expecting, that's what we've been told. Anything else is a bonus. I must admit that my reserved and pragmatic approach is being tested to the limit with all these 'research' posts. #itscominghome

When this is all over, I'd love to know what went wrong with that deal. Tim was pretty sure it was coming and yet here we are years later.

Said this before. When the party phrase was first coined the was probably less than 1.5 billion shares in issue. With subsequent placings, this should now be the 20p party?

What Thoth said.

I don't think we'll ever see royalties though. We'll be bought out before that happens. I'm thinking 2 licences for TYK2 , both small upfront but backend loaded with 3-400 million in milestones and a buyout when both are in PII. CHK1 might be in PIII by then too. 2p in the next few weeks would be ace!!

Stoney - When we got the licence for CHK1. The SP doubled overnight buy then quickly retraced. That deal was worth 1.6 million and a potential £70 mil in milestones. We've too many shares in circulation to do a PYC. We'd have to go from a MC of less than 25 mill to one of a billion. If the deal isn't worth 1 billion it ain't going to happen.

Agree with Ahfam but I fear we are doing 2 + 2 and getting 28p instead of 1.5 - 2p which I think is more realistic.

Hey Utar. I don't think the big pay day is coming either. All Tim said was candidate selection, mid year. I think that's exactly what we'll get. However, some of that Sierra money is for us. I've no doubt in that so I think it's a timing thing and that news has to come in a certain order. All will be revealed soon enough. IMO, we are still a year away from the big one.

Sorry, wrong link. https://www.ft.com/content/7b045aa2-7cef-11e8-bc55-50daf11b720d

All this heat is good for SAR. http://e.endpointsnews.com/t/t-l-uhyklhy-nkjiyldii-i/

More than happy to be wrong here Ahfam :-)

I still think there is a year to go. IMO, candidate selection will be followed by a milestone which should give us enough to take TYK2 into clinics then we will get a licensing deal or two to push us into double figures 10p plus. Then it will be squeaky bum time until a buyout or a trial failure!

I know this sounds weird but i think the potential of our compounds may be qualifying us out of a takeover\buyout. We haven't seen the full CHK1 data yet but, if it's as good as we think then, going on other similar deals CHK1 could be worth £800+ million already and we'd hopefully get 27% of that. Then we have TYK2, same pedigree as CHK1 and again based on similar deals, we could be looking at 300 - 400 million for each, cancer and autoimmune. Aurora is an unknown right now but if the solubility is overcome we could be looking at £200 million for that. And finally, we have the building blocks of the SKIL platform. This alone will be worth 100's of millions if all the above work. What I'm trying to get at is, big pharma may want more evidence before they commit over billion. Biotech is hotting up stateside and hopefully, that sentiment will drip feed into the AIM market. I'd be happy with a milestone and a SP of 2p right now but I do think the fabled 28p is the end game here. The above is not an in depth valuation, it's just a result of me sitting in the garden all weekend reading Endpoints and noting deal sizes for preclinical and clinical deals. DYOR GLA

It's really easy to get swept up in the excitement on share boards. What you really need to ask yourself is, if you didn't frequent these boards, what would you be expecting to happen? The only things we know for certain are. Candidate selection is due mid 2018, CHK1 has gone into PII and Sierra has raised a lot of cash. That's it, the rest is speculation from others here. For what it's worth. IMO, Worst case short term scenario is candidate selection and a milestone and this might give us enough to take one of the TYK2 into clinics. I'm not thinking about best case scenario, we don't have enough concrete information.

But will 'they are stating facts' be a valid reason?

Arrg, you've ruined the 13.67 Price now. it's back down to 0.85! You've just lost me £300k :-)

200 mil would be enough to honour our milestones and a bit for our trouble.

I'm not sure about the trades but I have a funny feeling a deal is in negotiation and I think there is more than 2 players. All the little things over the last couple of months are adding up. Aurora back in-house, change of joint broker and the Sierra raise. I wouldn't be surprised if we are selling up. The Sierra money could be them to keep CHK1 and A N Another party will be taking the rest. I'm thinking some bigger news will drop before we get anything from Sierra. Might be completely wrong but something feels weird.

Aa111 - I take 20% profit on other shares all the time. Not here though. My original target here was 3 - 5p but looking at other (very) similar deals in the sector in the last couple of years. SAR could easily 10 bag on one good upfront. It's happened recently elsewhere. Why not here? If not, I"ll take 3 - 5p.